$OGEN
ORAGENICS INC Stock $ogen

$ogen Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222032121 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q4
Revenue	$0.00	$86.05K	$86.99K
YoY Change	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$883.6K	$1.215M	$1.078M
YoY Change	-18.02%	43.43%	-9.92%
% of Gross Profit
Research & Development	$1.412M	$2.825M	$1.310M
YoY Change	7.75%	-20.37%	-60.89%
% of Gross Profit
Depreciation & Amortization	$13.08K	$12.74K	$6.420K
YoY Change	103.74%	32.16%	-50.08%
% of Gross Profit
Operating Expenses	$2.296M	$4.040M	$2.388M
YoY Change	-3.88%	-8.08%	-47.5%
Operating Profit		-$3.954M
YoY Change		-10.03%
Interest Expense	$61.18K	$5.228K	$8.700K
YoY Change	603.22%	-51.19%	11.83%
% of Operating Profit
Other Income/Expense, Net	-$3.420K	$35.92K	-$160.00
YoY Change	2037.5%		-73.33%
Pretax Income	-$2.238M	-$3.918M	-$2.293M
YoY Change	-2.39%	-10.63%	-48.0%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$2.238M	-$3.918M	-$2.293M
YoY Change	-2.39%	-10.63%	-48.0%
Net Earnings / Revenue		-4552.91%	-2635.45%
Basic Earnings Per Share		-$0.03
Diluted Earnings Per Share	-$1.01	-$33.56K	-$19.69K
COMMON SHARES
Basic Shares Outstanding	117.4M shares	116.7M shares
Diluted Shares Outstanding		1.946M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.43M	$13.95M	$27.27M
YoY Change	-58.09%	-53.42%	54.57%
Cash & Equivalents	$11.43M	$13.95M	$27.27M
Short-Term Investments
Other Short-Term Assets	$2.863M	$562.0K	$434.7K
YoY Change	558.56%	-4.19%	26.69%
Inventory
Prepaid Expenses	$2.845M		$416.8K
Receivables
Other Receivables			$6.987K
Total Short-Term Assets	$14.29M	$14.51M	$27.71M
YoY Change	-48.43%	-52.47%	54.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$121.1K	$132.4K	$523.6K
YoY Change	-76.88%	-76.18%	-24.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$468.5K	$527.8K	$523.6K
YoY Change	-10.52%	-5.04%	-24.97%
TOTAL ASSETS
Total Short-Term Assets	$14.29M	$14.51M	$27.71M
Total Long-Term Assets	$468.5K	$527.8K	$523.6K
Total Assets	$14.76M	$15.04M	$28.23M
YoY Change	-47.72%	-51.62%	51.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.124M	$871.1K	$947.6K
YoY Change	18.64%	-42.81%	0.81%
Accrued Expenses	$812.9K	$202.0K	$194.3K
YoY Change	318.42%	6.2%	9.82%
Deferred Revenue
YoY Change
Short-Term Debt	$267.6K	$424.9K	$303.4K
YoY Change	-11.79%	-11.89%	32.94%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.596M	$1.498M	$1.445M
YoY Change	10.45%	-31.77%	7.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$152.4K	$204.6K	$299.5K
YoY Change	-49.11%	-41.41%	-39.34%
Total Long-Term Liabilities	$152.4K	$204.6K	$299.5K
YoY Change	-49.11%	-41.41%	-39.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.596M	$1.498M	$1.445M
Total Long-Term Liabilities	$152.4K	$204.6K	$299.5K
Total Liabilities	$1.749M	$1.703M	$1.745M
YoY Change	0.23%	-33.1%	-4.97%
SHAREHOLDERS EQUITY
Retained Earnings	-$185.6M	-$185.3M	-$171.3M
YoY Change	8.34%
Common Stock	$2.025K	$117.3K	$116.4K
YoY Change	-98.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.01M	$13.34M	$26.49M
YoY Change
Total Liabilities & Shareholders Equity	$14.76M	$15.04M	$28.23M
YoY Change	-47.72%	-51.62%	51.13%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q4
OPERATING ACTIVITIES
Net Income	-$2.238M	-$3.918M	-$2.293M
YoY Change	-2.39%	-10.63%	-48.0%
Depreciation, Depletion And Amortization	$13.08K	$12.74K	$6.420K
YoY Change	103.74%	32.16%	-50.08%
Cash From Operating Activities	-$2.433M	-$3.776M	-$1.884M
YoY Change	29.1%	-27.11%	-48.11%
INVESTING ACTIVITIES
Capital Expenditures	$3.440K	-$37.03K	-$19.76K
YoY Change	-117.41%	53.52%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$3.440K	-$37.03K	-$19.76K
YoY Change	-82.59%	53.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-88.00K	-103.5K	-779.0K
YoY Change	-88.7%	-117.9%	-106.94%
NET CHANGE
Cash From Operating Activities	-2.433M	-3.776M	-1.884M
Cash From Investing Activities	-3.440K	-37.03K	-19.76K
Cash From Financing Activities	-88.00K	-103.5K	-779.0K
Net Change In Cash	-2.524M	-3.916M	-2.683M
YoY Change	-5.92%	-15.34%	-135.32%
FREE CASH FLOW
Cash From Operating Activities	-$2.433M	-$3.776M	-$1.884M
Capital Expenditures	$3.440K	-$37.03K	-$19.76K
Free Cash Flow	-$2.436M	-$3.739M	-$1.865M
YoY Change	30.65%	-27.48%	-48.65%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001174940
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022Q3	OGEN	Stock Issued During Period Value Conversion Of Series B Preferred Stock To Common Stock StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock		usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
	OGEN	Conversion Of Stock Amount Converted ConversionOfStockAmountConverted		usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
	OGEN	Conversion Of Stock Amount Issued ConversionOfStockAmountIssued		usd
	OGEN	Stock Dividend On Series C Preferred Stock StockDividendOnSeriesCPreferredStock		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2021	OGEN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2021	OGEN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	OGEN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	OGEN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-32188
	dei	Entity Registrant Name EntityRegistrantName	ORAGENICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-3410522
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4902 Eisenhower Blvd.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 125
	dei	Entity Address City Or Town EntityAddressCityOrTown	Tampa
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33634
	dei	City Area Code CityAreaCode	813
	dei	Local Phone Number LocalPhoneNumber	286-7900
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	OGEN
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	117449809	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13951054	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27265703	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	6987	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	561952	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	434699	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	14513006	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	27707389	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	132382	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	45708	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	395435	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	477882	usd
CY2022Q3	us-gaap	Assets Assets	15040823	usd
CY2021Q4	us-gaap	Assets Assets	28230979	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	871084	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	947574	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	424924	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	303416	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	201973	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	194270	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1497981	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1445260	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	204593	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	299520	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	204593	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	299520	usd
CY2022Q3	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	117304809	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	116394806	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	116394806	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	117305	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	116395	usd
CY2021Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	1592723	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	2656713	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	117304809	shares
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	196888079	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	194987219	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-185259858	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171274128	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	13338249	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	26486199	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15040823	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28230979	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86047	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	131521	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2824598	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3547321	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10595842	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9275800	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1215009	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	847134	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3590892	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4194103	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	4039607	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	4394455	usd
	us-gaap	Operating Expenses OperatingExpenses	14186734	usd
	us-gaap	Operating Expenses OperatingExpenses	13469903	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3953560	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4394455	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14055213	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13469903	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	41634	usd
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	17760	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	68909	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	62047	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	5228	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	7053	usd
	us-gaap	Interest Expense InterestExpense	9290	usd
	us-gaap	Interest Expense InterestExpense	10654	usd
CY2022Q3	OGEN	Local Business Tax LocalBusinessTax	489	usd
CY2021Q3	OGEN	Local Business Tax LocalBusinessTax	-2	usd
	OGEN	Local Business Tax LocalBusinessTax	1469	usd
	OGEN	Local Business Tax LocalBusinessTax	1198	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11333	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	670	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	35917	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10709	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	69483	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	50865	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3917643	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4383746	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13985730	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13419038	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3917643	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4383746	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13985730	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13419038	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116744807	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116262938	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116511473	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	111748586	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	26486199	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	90247	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-6035394	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	20541052	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	278988	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4032693	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16787347	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	468545	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3917643	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	13338249	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	16844595	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1123761	usd
CY2021Q1	OGEN	Redemption Of Preferred Stock RedemptionOfPreferredStock	-5635672	usd
CY2021Q1	OGEN	At The Market Offering Net Of Expenses AtTheMarketOfferingNetOfExpenses	26676392	usd
CY2021Q1	OGEN	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	2261336	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	231140	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5219945	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	36050467	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	267140	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3815347	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	32733400	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	100769	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	96000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4383746	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	28546423	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13985730	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13419038	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	31594	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	34817	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	10964	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	837780	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1455670	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-6987	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-401176	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-356756	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-76490	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	586177	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12795647	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10985618	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	12000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	124081	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24123	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-112081	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-24123	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	406921	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	346138	usd
	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	5635672	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	363140	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2261336	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	26676392	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-406921	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23319058	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13314649	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	12309317	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27265703	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17639575	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13951054	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29948892	usd
	us-gaap	Interest Paid Net InterestPaidNet	9290	usd
	us-gaap	Interest Paid Net InterestPaidNet	10654	usd
	us-gaap	Notes Assumed1 NotesAssumed1	528429	usd
	us-gaap	Notes Assumed1 NotesAssumed1	600169	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	415169	usd
	OGEN	Conversion Of Stock Amount Converted ConversionOfStockAmountConverted	648821	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	400	usd
	OGEN	Conversion Of Stock Amount Issued ConversionOfStockAmountIssued	510	usd
	OGEN	Stock Dividend On Series C Preferred Stock StockDividendOnSeriesCPreferredStock	1117531	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13985730	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12795647	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-185259858	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_z5EfY0jCtWka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal area of estimation reflected in the consolidated financial statements is stock-based compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zG3Q8KbjJlC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of September 30, 2022, the uninsured portion of this balance was $<span id="xdx_90D_eus-gaap--CashUninsuredAmount_c20220930_pp0p0" title="Uninsured portion of balance">13,701,054</span>. As of December 31, 2021, the uninsured portion of this balance was $<span id="xdx_907_eus-gaap--CashUninsuredAmount_c20211231_pp0p0" title="Uninsured portion of balance">27,015,703</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2022Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	13701054	usd
CY2021Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	27015703	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	468545	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	100769	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	837780	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1455670	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6724402	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.95
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M26D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2773	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2952500	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.34
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	4500	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	12.00
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	726998	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.94
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8945404	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.68
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M28D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6832900	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.77
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M14D
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	517724	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	20513145	shares
CY2020Q4	OGEN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	1.36
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	2472573	shares
CY2021	OGEN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	0.91
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	18040572	shares
CY2021Q4	OGEN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	1.42
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	48387	shares
	OGEN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice	3.10
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	17992185	shares
CY2022Q3	OGEN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	1.41
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	17992185	shares
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	424924	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	303416	usd
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y11M19D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y5M12D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0577	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0570	pure
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	54415	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	219093	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	156605	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	430113	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	23547	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	406566	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	171388	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	171040	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2138	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1159	usd
	us-gaap	Lease Cost LeaseCost	173526	usd
	us-gaap	Lease Cost LeaseCost	172199	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	176165	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	170354	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	0	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	0	shares

Files In Submission

Name	View Source	Status
0001493152-22-032121-index-headers.html	Edgar Link	pending
0001493152-22-032121-index.html	Edgar Link	pending
0001493152-22-032121.txt	Edgar Link	pending
0001493152-22-032121-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
ogen-20220930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ogen-20220930_lab.xml	Edgar Link	unprocessable
ogen-20220930_cal.xml	Edgar Link	unprocessable
ogen-20220930_def.xml	Edgar Link	unprocessable
ogen-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OGEN
ORAGENICS INC Stock $ogen

2022 Q4 Form 10-Q Financial Statement

#000149315222032121 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OGEN ORAGENICS INC Stock $ogen

2022 Q4 Form 10-Q Financial Statement

#000149315222032121 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OGEN
ORAGENICS INC Stock $ogen